New study underway in the US and approval from the Food and Drug Administration (FDA)
The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, was held as scheduled on Friday. As previously announced, it was a formal meeting for the start-up and review of routines and equipment.– I am very excited about the study and look forward to start patient recruitment, says James A. Eastham, Chief of the Urology Service at Memorial Sloan Kettering Cancer Center. FDA has approved SpectraCure's new protocol for clinical trials, enabling more patients to be treated at a faster rate, which increases the basis of analysis for further clinical